5WFO

Ligand-bound Ras:SOS:Ras complex

Summary for 5WFO

• Entry DOI: 10.2210/pdb5wfo/pdb
• Descriptor: GTPase HRas, Son of sevenless homolog 1, MAGNESIUM ION, ... (6 entities in total)
• Functional Keywords: ras, sos, oncoprotein-dna binding protein complex, signaling protein
• Biological source: Homo sapiens (Human); More
• Cellular location: Cell membrane. Isoform 2: Nucleus: P01112
• Total number of polymer chains: 3
• Total formula weight: 95327.56

Authors

Sun, Q.,Phan, J.,Burns, M.C.,Fesik, S.W. (deposition date: 2017-07-12, release date: 2018-05-23, Last modification date: 2023-10-04)

Primary citation

Burns, M.C.,Howes, J.E.,Sun, Q.,Little, A.J.,Camper, D.V.,Abbott, J.R.,Phan, J.,Lee, T.,Waterson, A.G.,Rossanese, O.W.,Fesik, S.W.
High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
Anal. Biochem., 548:44-52, 2018

PubMed Abstract: K-RAS is mutated in approximately 30% of human cancers, resulting in increased RAS signaling and tumor growth. Thus, RAS is a highly validated therapeutic target, especially in tumors of the pancreas, lung and colon. Although directly targeting RAS has proven to be challenging, it may be possible to target other proteins involved in RAS signaling, such as the guanine nucleotide exchange factor Son of Sevenless (SOS). We have previously reported on the discovery of small molecules that bind to SOS1, activate SOS-mediated nucleotide exchange on RAS, and paradoxically inhibit ERK phosphorylation (Burns et al., PNAS, 2014). Here, we describe the discovery of additional, structurally diverse small molecules that also bind to SOS1 in the same pocket and elicit similar biological effects. We tested >160,000 compounds in a fluorescence-based assay to assess their effects on SOS-mediated nucleotide exchange. X-Ray structures revealed that these small molecules bind to the CDC25 domain of SOS1. Compounds that elicited high levels of nucleotide exchange activity in vitro increased RAS-GTP levels in cells, and inhibited phospho ERK levels at higher treatment concentrations. The identification of structurally diverse SOS1 binding ligands may assist in the discovery of new molecules designed to target RAS-driven tumors.

PubMed: 29444450
DOI: 10.1016/j.ab.2018.01.025

Experimental method

X-RAY DIFFRACTION (1.99 Å)